Response to anti-HER2 neoadjuvant chemotherapy in HER2-positive invasive breast cancers with different HER2 FISH patterns.

Hong LvQian-Ming BaiMing LiMeng-Yuan CaiShu-Ling ZhouYin LiuZhong-Hua WangRuo-Hong ShuiHong-Fen LuXiao-Li Xu Bao-Hua YuXiao-Yu TuRui BiYu-Fan ChengXiao-Yan ZhouZhi-Min ShaoWen-Tao Yang

Published in: Journal of clinical pathology (2024)

Patients with HER2/CEP17≥2.0 and HER2 copy numbers ≥4.0 and <6.0 do not benefit to the same extent from current anti-HER2 therapies as FISH-positive patients with other patterns.

Keyphrases

neoadjuvant chemotherapy
locally advanced
lymph node
sentinel lymph node
squamous cell carcinoma
radiation therapy
young adults
childhood cancer